Steven D. Averbuch

13.8k total citations · 5 hit papers
59 papers, 11.0k citations indexed

About

Steven D. Averbuch is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Steven D. Averbuch has authored 59 papers receiving a total of 11.0k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in Steven D. Averbuch's work include Lung Cancer Treatments and Mutations (22 papers), HER2/EGFR in Cancer Research (18 papers) and Colorectal Cancer Treatments and Studies (15 papers). Steven D. Averbuch is often cited by papers focused on Lung Cancer Treatments and Mutations (22 papers), HER2/EGFR in Cancer Research (18 papers) and Colorectal Cancer Treatments and Studies (15 papers). Steven D. Averbuch collaborates with scholars based in United States, United Kingdom and Spain. Steven D. Averbuch's co-authors include Roy S. Herbst, Michael Wolf, Joan H. Schiller, Ronald B. Natale, Giuseppe Giaccone, Judith Ochs, Danny Rischin, A. Feyereislova, José Baselga and Abderrahim Fandi and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Biological Chemistry.

In The Last Decade

Steven D. Averbuch

59 papers receiving 10.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

2003 2.4k citations Masahiro Fukuoka, Seiji Yano et al. Journal of Clinical Oncology profile →
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

2003 2.1k citations Roy S. Herbst, Karen Kelly et al. profile →
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

2004 1.4k citations Giuseppe Giaccone, Roy S. Herbst et al. Journal of Clinical Oncology profile →
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

2004 1.4k citations Roy S. Herbst, Giuseppe Giaccone et al. Journal of Clinical Oncology profile →
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

2002 683 citations José Baselga, Danny Rischin et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Steven D. Averbuch

Since Specialization

Citations

This map shows the geographic impact of Steven D. Averbuch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven D. Averbuch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven D. Averbuch more than expected).

Fields of papers citing papers by Steven D. Averbuch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven D. Averbuch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven D. Averbuch. The network helps show where Steven D. Averbuch may publish in the future.

Co-authorship network of co-authors of Steven D. Averbuch

This figure shows the co-authorship network connecting the top 25 collaborators of Steven D. Averbuch. A scholar is included among the top collaborators of Steven D. Averbuch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven D. Averbuch. Steven D. Averbuch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement 2018 ·Journal for ImmunoTherapy of Cancer ·Apostolia M. Tsimberidou, Laura A. Levit, Richard L. Schilsky, Steven D. Averbuch, Daniel Chen, John M. Kirkwood, Lisa M. McShane, Elad Sharon, Kathryn F. Mileham, Michael A. Postow	15
2	Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine 2008 ·Cancer ·Hui Huang, Jame Abraham, (unknown), Steven D. Averbuch, Maria J. Merino, Seth M. Steinberg, Karel Pacák, Tito Fojo	171
3	Gefitinib: phase II and III results in advanced non-small cell lung cancer 2004 ·Seminars in Oncology ·Karen Kelly, Steven D. Averbuch	15
4	Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors 2004 ·British Journal of Cancer ·G. Blackledge, Steven D. Averbuch	66
5	Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors 2004 ·Annals of Oncology ·Giuseppe Giaccone, J.L. González-Larriba, A.T. van Oosterom, Rosario Alfonso, Egbert F. Smit, Marc Martens, Godefridus J. Peters, W. J. F. van der Vijgh, Robert P. Smith, Steven D. Averbuch, Abderrahim Fandi	52
6	Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer breakdown → 2003 ·Journal of Clinical Oncology ·Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, Tomohide Tamura, Kazuhiko Nakagawa, Jean‐Yves Douillard, Yutaka Nishiwaki, Johan Vansteenkiste, Shinzoh Kudoh, Danny Rischin, Richard Eek, Takeshi Horai, Kazumasa Noda, Ichiro Takata, Egbert F. Smit, Steven D. Averbuch, (unknown), A. Feyereislova, (unknown), José Baselga	2392
7	Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with genfinitib (ZD1839) 2003 ·Journal of Clinical Oncology ·Federico Rojo, Josep Tabernero, Eric Van Cutsem, Atsushi Ohtsu, (unknown), Wasaburo Koizumi, Marc Peeters, Steven D. Averbuch, Neil J. Gallagher, José Baselga	21
8	The Impact of Gefitinib on Epidermal Growth Factor Receptor Signaling Pathways in Cancer 2003 ·Clinical Lung Cancer ·Steven D. Averbuch	2
9	Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. 2003 ·PubMed ·Patricia LoRusso, Roy S. Herbst, Danny Rischin, Malcolm Ranson, Hilary Calvert, Éric Raymond, Dirk Kieback, Stan B. Kaye, Luca Gianni, Adrian L. Harris, Thomas Björk, Anne Marie Maddox, Mace L. Rothenberg, Eric J. Small, Eric H. Rubin, A. Feyereislova, Anne Heyes, Steven D. Averbuch, Judith Ochs, José Baselga	40
10	The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. 2001 ·PubMed ·Mark M. Moasser, Andrea Basso, Steven D. Averbuch, Neal Rosen	437
11	ZD1839 (???Iressa???),??? as an Anticancer Agent 2000 ·Drugs* ·(unknown), Steven D. Averbuch	254
12	Phase I trial of ZD9331 given as a 30 minute infusion on days 1 and 8 with cycles repeated every 3 weeks 1998 ·UCL Discovery (University College London) ·(unknown), Philip Beale, Ruth Plummer, Martin Highley, (unknown), I. Judson, Rhodri Smith, Michael G. Hutchison, Steven D. Averbuch, Kaitlin J. Mayne	2
13	Hypertensive crises induced by treatment of malignant pheochromocytoma with a combination of cyclophosphamide, vincristine, and dacarbazine 1994 ·Medical and Pediatric Oncology ·(unknown), Peter V. Dicpinigaitis, Howard W. Bruckner, William M. Manger, Steven D. Averbuch	17
14	Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine 1994 ·Cancer ·(unknown), Steven D. Averbuch, Douglas W. Ball, A de Bustros, Stephen B. Baylin, William P. McGuire	89
15	New bisphosphonates in the treatment of bone metastases 1993 ·Cancer ·Steven D. Averbuch	49
16	Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. 1993 ·Journal of Clinical Oncology ·S R Nussbaum, Raymond P. Warrell, Robert K. Rude, J. E. Glusman, J P Bilezikian, Andrew F. Stewart, (unknown), (unknown), Steven D. Averbuch, B. J. Gertz	45
17	Pheochromocytoma presenting as a skull metastasis with massive extracranial and intracranial extension 1990 ·Neurosurgery ·(unknown), (unknown), (unknown), Steven D. Averbuch, Rosario A. Zappulla	9
18	Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma. 1989 ·Journal of Clinical Oncology ·Lee J. Helman, P S Cohen, Steven D. Averbuch, Jonathan M. Cooper, Harry R. Keiser, Mark A. Israel	55
19	Malignant Pheochromocytoma: Effective Treatment with a Combination of Cyclophosphamide, Vincristine, and Dacarbazine 1988 ·Annals of Internal Medicine ·Steven D. Averbuch, Caryn Steakley, (unknown), Edward P. Gelmann, D. S. Goldstein, Robin Stull, Harry R. Keiser	290
20	Experimental chemotherapy-induced skin necrosis in swine. Mechanistic studies of anthracycline antibiotic toxicity and protection with a radical dimer compound. 1988 ·Journal of Clinical Investigation ·Steven D. Averbuch, (unknown), Giorgio Gaudiano, Jean‐Baptiste Stern, Tad H. Koch, N R Bachur	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact